Last month in the first of a two-part series, START-UP provided a top-level view of investments in private CNS companies across biopharma, medtech and diagnostics firms from 2010 through July 2015 using data from Informa’s Strategic Transactions. (See [A#2015900161].) Part 1 focused on biopharma, which took 73%, or $3.8 billion, of the total $5.2 billion brought in across industries for the period. The group broke a fundraising record, had M&A exits worth a potential aggregate $7.2 billion and scored yet more money through some hefty tie-ups with big pharma.
In Part 2 we delve into private neurology medtech and diagnostic fundraising and exits, which paint a slightly different picture. Investors and money were scarcer for this group and, unlike their well-funded early-stage biopharma counterparts, only those medtech and diagnostic firms with near-market or already marketed products were rewarded